Pomegranate Interactions

Pomegranate inhibits the drug-metabolizing enzyme CYP3A4 in laboratory and animal studies, raising a theoretical concern that it could increase blood levels of CYP3A4-dependent statins such as simvastatin, atorvastatin, and lovastatin. However, controlled human studies - including ones using simvastatin and a sensitive CYP3A4 probe drug - did not find a meaningful effect, so pomegranate should not be treated like grapefruit. Concentrated pomegranate extract supplements warrant more caution than the whole fruit.

Pomegranate contains punicalagins and other polyphenols that inhibit the liver enzymes CYP2C9 and CYP3A4 in laboratory and animal studies, which would slow warfarin metabolism. Case reports describe both a raised INR after heavy or newly started pomegranate juice intake and a falling INR after stopping a habitual juice habit. The effect appears to be genuine but infrequent, and consistency of intake matters more than total avoidance.

Pomegranate juice modestly lowers blood pressure on its own and can add to the blood-pressure-lowering effect of ACE inhibitors; it also contributes dietary potassium, which may compound the potassium-retaining effect of these drugs.